Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: BMS operates as a single-segment global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines in oncology, hematology, immunology, cardiovascular, and neuroscience. The company maintains a portfolio of growth products (e.g., Opdivo, Eliquis, Breyanzi) and legacy products facing generic competition.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $48,194 million | $48,300 million | (0.2%) |
| Net Earnings (GAAP) | $7,054 million | $(8,948 million) | Turnaround to Profit |
| Diluted EPS (GAAP) | $3.46 | $(4.41) | $7.87 increase |
| Diluted EPS (Non-GAAP) | $6.15 | $1.15 | $5.00 increase |
| Operating Cash Flow | $14,156 million | $15,190 million | (6.8%) |
| Net Debt Position | $(34,043 million) | $(38,470 million) | Decrease of $4.4 billion |
| R&D Expenses | $9,951 million | $11,159 million | (11%) |
| Acquired IPRD Expenses | $3,721 million | $13,373 million | (72%) |
Material Changes vs. Prior Period
- Revenue Stability: Total revenues remained relatively flat despite a 17% increase in the Growth Portfolio (driven by Opdivo, Breyanzi, and Camzyos). This growth was offset by a 15% decline in the Legacy Portfolio due to significant generic erosion of Revlimid (down 49%), Sprycel (down 62%), and Abraxane (down 58%).
- Profitability Surge: GAAP earnings swung from a loss of $8.9 billion in 2024 to a profit of $7.1 billion in 2025. This was primarily driven by a $9.7 billion reduction in Acquired IPRD charges (excluding the $12.1 billion Karuna charge in 2024) and lower amortization of acquired intangible assets as Revlimid and Pomalyst rights were fully amortized.
- Cost Management: Selling, general, and administrative (SG&A) expenses decreased 14% due to strategic productivity initiatives and lower acquisition-related cash settlements. R&D expenses decreased 11% due to lower impairment charges and productivity savings.
- Debt Reduction: The company reduced its net debt by $4.4 billion through strong operating cash flows, partially offset by dividend payments ($5.0 billion) and acquisition-related payments ($3.9 billion). In late 2025, BMS repurchased $8.7 billion of debt obligations.
Guidance, Outlook, and Risks
- Government Pricing Agreements: In December 2025, BMS announced a "U.S. Government Agreement" to provide Eliquis for free to the Medicaid program starting January 1, 2026, and to offer significant discounts on other products. In exchange, the company received tariff relief until 2029 and protection from future U.S. pricing mandates.
- IRA Impact: The Inflation Reduction Act (IRA) continues to impact pricing. The HHS set "maximum fair prices" for Eliquis (effective 2026) and Pomalyst (effective 2027). Orencia was selected for price negotiation starting in 2028.
- Patent Expirations: Significant generic erosion is expected to continue in 2026, particularly for Revlimid and Pomalyst in the U.S. and Eliquis in Europe, where generic entry has already begun in certain jurisdictions despite ongoing litigation.
- Pipeline Developments: Key approvals in 2025 included Breyanzi for new indications, Opdivo + Yervoy for HCC and CRC, and Camzyos for oHCM in Japan. However, some late-stage trials faced setbacks, including Camzyos for non-obstructive HCM and Opdualag for adjuvant melanoma.
- Strategic Productivity: Management expects to realize approximately $2.0 billion in cost savings by the end of 2027 through ongoing restructuring and operational streamlining.
Investor Verification Checklist
- Legacy Portfolio Erosion: Verify the actual revenue impact of generic entry for Revlimid and Pomalyst in Q1 2026, as licenses are no longer volume-limited.
- Government Agreement Terms: Monitor the financial impact of the December 2025 U.S. Government Agreement, specifically the cost of providing free Eliquis to Medicaid and the extent of tariff relief received.
- IRA Price Negotiations: Track the final "maximum fair price" determinations for Eliquis and Pomalyst and their effect on Medicare channel revenue in 2026 and 2027.
- Acquired IPRD Volatility: Assess future earnings stability given the high variability of Acquired IPRD charges, which dropped significantly in 2025 compared to 2024.
- Debt Maturities: Review the schedule of debt maturities ($8.9 billion through 2030) and the company's ability to service debt while maintaining dividend payments and R&D investment.